Investigational drug · Phase 2
SYH2069
Also called: group 1, group 2, group 3, group 4
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for T2DM (Type 2 Diabetes Mellitus), Overweight or Obesity.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "SYH2069"
First trial start
2026
Sep 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYH2069", any sponsor or status.
Conditions studied
As listed on its trial records.
- T2DM (Type 2 Diabetes Mellitus)
- Overweight or Obesity
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "SYH2069" as an intervention, largest first.
- Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.Pivotal-lookingNot yet recruiting
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT07803991 · 360 participants (planned) · Start Sep 1, 2026 · Primary completion Sep 30, 2027
Drug: SYH2069 Injection; SYH2069 Injection Placebo · For: Overweight or Obesity
Sites: Nanjing, China
- A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or MetforminPivotal-lookingNot yet recruiting
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT07796477 · 240 participants (planned) · Start Nov 6, 2026 · Primary completion Sep 28, 2027
Drug: SYH2069 Injection (group 1); SYH2069 Injection (group 2) and 4 more · For: T2DM (Type 2 Diabetes Mellitus)
Sites: Nanjing, China
- A Study of SYH2069 Injection in Healthy ParticipantsPivotal-lookingActive, not recruiting
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT07736391 · 104 participants · Start Jan 10, 2026 · Primary completion Jul 30, 2026
Drug: SYH2069 Injection; Placebo · For: Overweight or Obesity; Diabetes
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
- Comparison of the Clinical Outcomes Between Gel Immersion and Underwater Endoscopic Mucosal Resection for Superficial Non-ampullary Duodenal Epithelial Tumors (With Video).
Otsuka M, Hikichi T, Nakamura J, et al. · DEN Open 2027
- Efficiency and Safety of Endoscopic Injection Sclerotherapy With Ligation for Esophageal Varices: A Retrospective Study.
Maki K, Haga H, Hoshikawa K, et al. · DEN Open 2027
- Breast metaplastic squamous cell carcinoma associated with a squamous-lined cyst: A potential distinct clinicopathologic subset.
Han M, Schmolze D, Arias-Stella J, et al. · Ann Diagn Pathol 2027
- Comparing outcomes of onlay humeral stem designs in reverse total shoulder arthroplasty: a systematic review.
Daher N, Mazeh M, Castle JP, et al. · JSES Rev Rep Tech 2027
- Coixol attenuates Ulcerative Colitis by modulating the ILC3 response via the Wnt/β-catenin pathway.
Ma J, Yin Q, Zhou Y, et al. · J Ethnopharmacol 2027
- GnRH and PGF2α administered at the time of AI differently affect conception rates of non-estrous Nelore cows according to Body Condition Score.
Diniz JHW, Cunha ECR, Marques Savioli H, et al. · Theriogenology 2027
Also in development for T2DM (Type 2 Diabetes Mellitus)
- ASC30 A1ASC30Phase 35 trials
Ascletis Pharma (China) Co., Limited · Chronic Weight Management, Obesity, Overweight
- RAY1225Phase 35 trials
Guangdong Raynovent Biotech Co., Ltd · Obesity, T2DM, T2DM (Type 2 Diabetes Mellitus)
- HTD1801Berberine UrsodeoxycholatePhase 34 trials
Shenzhen HighTide Biopharmaceutical Ltd. · T2DM (Type 2 Diabetes Mellitus), Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
- DWP16001Phase 32 trials
Daewoong Pharmaceutical Co. LTD. · Type 2 Diabetic Nephropathy, T2DM (Type 2 Diabetes Mellitus)
- DWC202518Phase 31 trial
Daewoong Pharmaceutical Co. LTD. · T2DM (Type 2 Diabetes Mellitus)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.